Facioscapulohumeral muscular dystrophy (MD), commonly known
as FSHD or FSH, is a complex, inheritable muscle disease with an
etiology that is rapidly becoming more elucidated; it appears to have
varying molecular and genetic determinants with commensurate
differences in disease progression. With this paper, Raymond A.
Huml, MS, DVM, RAC, Vice President of QuintilesIMS Global
Biosimilars Strategic Planning, and his team provide an overview of
FSHD, discuss major clinical symptoms and ramifications of disease
progression, provide a regulatory overview, and discuss two of the
more commonly used surgical procedures to treat FSHD.